Episode

Thomas Phillips: I’m Against the FDA’s Drug Approval Process | 05-30-26

Podcast
77 WABC MiniCasts
Published
May 30, 2026
Duration seconds
522
Processing state
not_requested
Canonical source
https://www.podtrac.com/pts/redirect.mp3/traffic.megaphone.fm/WABC8670782734.mp3
Audio
https://www.podtrac.com/pts/redirect.mp3/traffic.megaphone.fm/WABC8670782734.mp3
JSON
/v1/public/podcasts/77-wabc-minicasts-5907352/episodes/thomas-phillips-i-m-against-the-fda-s-drug-approval-process-05-30-26
Markdown
/podcast/77-wabc-minicasts-5907352/thomas-phillips-i-m-against-the-fda-s-drug-approval-process-05-30-26.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/77-wabc-minicasts-5907352/episodes/thomas-phillips-i-m-against-the-fda-s-drug-approval-process-05-30-26/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/77-wabc-minicasts-5907352/thomas-phillips-i-m-against-the-fda-s-drug-approval-process-05-30-26.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Thomas Phillips argues that the lengthy FDA drug approval process is a significant barrier to both public health and economic growth. While the government successfully evaluates product safety quickly, the authors contend that the secondary mandate to prove long-term effectiveness creates a "one-size-fits-all" bureaucratic delay that can last a decade. By shortening this timeline and allowing the private sector and individual patients to determine a treatment's utility, the study suggests the United States could unlock up to $48 trillion in economic benefits. Learn more about your ad choices. Visit megaphone.fm/adchoices